Literature DB >> 25979723

Psoriatic Arthritis Mutilans: Characteristics and Natural Radiographic History.

Deepak R Jadon1, Gavin Shaddick2, William Tillett2, Eleanor Korendowych2, Graham Robinson2, Nicola Waldron2, Charlotte Cavill2, Neil J McHugh2.   

Abstract

OBJECTIVE: (1) To compare clinical characteristics of patients with psoriatic arthritis (PsA) with PsA mutilans (PAM) and without PAM, and (2) to determine the rate of PAM radiographic progression.
METHODS: A retrospective cohort study was conducted of all patients with PsA attending a teaching hospital. The most recent hand and feet radiographs were screened for PAM. Serial radiographs (earliest to most recent) were quantitatively scored for osteolysis, erosion, joint space narrowing, and osteoproliferation.
RESULTS: Out of the 610 cases, 36 PsA cases had PAM (5.9%). PAM cases were younger at diagnosis of PsA than non-PAM cases (p = 0.04), had more prevalent psoriatic nail dystrophy (OR 5.43, p < 0.001), and worse health assessment questionnaire score (1.25 vs 0.63, p < 0.04). Radiographic axial disease (OR 2.31, adjusted p = 0.03) and especially radiographic sacroiliitis (OR 2.99, adjusted p = 0.01) were more prevalent in PAM. PAM were more likely than non-PAM cases to have used a disease-modifying antirheumatic drug (DMARD; OR 16.36, p < 0.001). Out of 33 cases, 29 PAM cases had initiated a synthetic DMARD and 4/13 had initiated anti-tumor necrosis factor (anti-TNF) prior to first demonstration of PAM. A median 5 radiographs were scored for each PAM case (interquartile range 3-7). PAM progressed from monoarticular (60%) to polyarticular (80%) involvement. Osteolysis was initially rapid and progressive in the hands and feet, tapering later during disease course. Nail dystrophy predicted more severe osteolysis (p = 0.03).
CONCLUSION: Compared with non-PAM cases, PAM cases have earlier age at PsA diagnosis, poorer function, more prevalent nail dystrophy, and more radiographic axial disease/sacroiliitis. The rate of osteolysis is higher in earlier disease, and more severe in those with nail dystrophy. DMARD and anti-TNF therapy appear not to prevent PAM occurrence.

Entities:  

Keywords:  MALFORMED NAIL RADIOGRAPHS; NATURAL HISTORY; PSORIATIC ARTHRITIS; TUMOR NECROSIS FACTOR-α

Mesh:

Substances:

Year:  2015        PMID: 25979723     DOI: 10.3899/jrheum.150083

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

Review 1.  Psoriatic arthritis and psoriasis: differential diagnosis.

Authors:  Maddalena Napolitano; Francesco Caso; Raffaele Scarpa; Matteo Megna; Angela Patrì; Nicola Balato; Luisa Costa
Journal:  Clin Rheumatol       Date:  2016-05-07       Impact factor: 2.980

Review 2.  Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management.

Authors:  Francesco Caso; Marco Tasso; Maria Sole Chimenti; Luca Navarini; Carlo Perricone; Nicolò Girolimetto; Rosario Peluso; Antonio Del Puente; Antonella Afeltra; Roberto Perricone; Leonardo Punzi; Raffaele Scarpa; Luisa Costa
Journal:  Drugs Aging       Date:  2019-10       Impact factor: 3.923

3.  Radiographic scoring systems for psoriatic arthritis are insufficient for psoriatic arthritis mutilans: results from the Nordic PAM Study.

Authors:  Leena Laasonen; Ulla Lindqvist; Lars Iversen; Leif Ejstrup; Thorarinn Jonmundsson; Mona Ståhle; Bjorn Gudbjornsson
Journal:  Acta Radiol Open       Date:  2020-04-27

4.  EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.

Authors:  Laure Gossec; Xenofon Baraliakos; Andreas Kerschbaumer; Maarten de Wit; Iain McInnes; Maxime Dougados; Jette Primdahl; Dennis G McGonagle; Daniel Aletaha; Andra Balanescu; Peter V Balint; Heidi Bertheussen; Wolf-Henning Boehncke; Gerd R Burmester; Juan D Canete; Nemanja S Damjanov; Tue Wenzel Kragstrup; Tore K Kvien; Robert B M Landewé; Rik Jozef Urbain Lories; Helena Marzo-Ortega; Denis Poddubnyy; Santiago Andres Rodrigues Manica; Georg Schett; Douglas J Veale; Filip E Van den Bosch; Désirée van der Heijde; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2020-06       Impact factor: 27.973

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.